At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed stage III or IV ovarian epithelial or primary peritoneal serous carcinoma
- ✓Optimal (≤1 cm residual) or suboptimal residual disease after initial surgery
- ✓GOG performance status 0-2
- ✓Prior borderline ovarian tumor allowed if no prior chemotherapy
- ✕Germ cell tumors, sex cord-stromal tumors, carcinosarcomas, or mixed Müllerian tumors
- ✕Low malignant potential tumors including micropapillary serous carcinomas
- ✕Mucinous primary peritoneal carcinoma
- ✕Metastatic carcinomas from other sites to the ovary
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma
In Brief
A Phase 3 clinical trial evaluating Paclitaxel, Carboplatin, and 4 other interventions for Primary Peritoneal Carcinoma and 2 related conditions. Completed, enrolled 4,312 participants across 1 site.
Detailed Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have stage III or stage IV ovarian cancer or primary peritoneal cancer.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given IV
Undergo surgery